Jeremy Peck
MOHS-Micrographic Surgery · Richland, WANPI 1457514689
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 636 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 25.1% of the total. 2025 is the largest year on record at $2,627, 2.9 times the $895 reported in 2019. Among mohs-micrographic surgery clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 636 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$2K
- Lilly USA, LLC$862
- UCB, Inc.$559
- Sun Pharmaceutical Industries Inc.$482
- Amgen$428
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,77794%
- Education$5216%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 182 | $2,330 |
| Johnson & Johnson | 157 | $1,921 |
| Lilly USA, LLC | 44 | $862 |
| UCB, Inc. | 33 | $559 |
| Sun Pharmaceutical Industries Inc. | 20 | $482 |
| Amgen | 20 | $428 |
| Sanofi | 21 | $405 |
| Novartis | 23 | $317 |
| E.r. Squibb & Sons, L.L.C. | 18 | $239 |
| Organogenesis Inc. | 20 | $216 |
| LEO Pharma Inc. | 9 | $168 |
| Dermavant Sciences, Inc. | 12 | $161 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 11 | $151 |
| Pfizer | 9 | $147 |
| Arcutis Biotherapeutics, Inc. | 8 | $145 |
| Biowound Solutions, Inc. | 10 | $137 |
| Revance Therapeutics, Inc. | 4 | $127 |
| Bristol Myers Squibb | 10 | $114 |
| Galderma Laboratories, L.p. | 5 | $85 |
| Incyte Corporation | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Dermira, Inc. | 2 | $41 |
| Biofrontera Inc. | 2 | $31 |
| Organon | 4 | $31 |
| Mimedx Group, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $14 |
| Prugen, Inc. Pharmaceuticals | 1 | $14 |
| Taro Pharmaceuticals USA, Inc. | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $12 |
How this compares
$9,298 in reported general payments places this provider in the 95th percentile of 38 mohs-micrographic surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 13 | $292,626 |
| Dupixent PenDupilumab | 53 | $229,469 |
| RinvoqUpadacitinib | 28 | $177,083 |
| Clobetasol Propionate | 228 | $13,832 |
| Triamcinolone Acetonide | 353 | $3,271 |
| Tacrolimus | 13 | $2,283 |
| Doxycycline Hyclate | 103 | $2,263 |
| Imiquimod | 66 | $1,269 |
| Tretinoin | 13 | $948 |
| Terbinafine Hcl | 21 | $537 |
| Hydrocortisone | 63 | $333 |
| ValacyclovirValacyclovir Hcl | 17 | $289 |
| Nystatin | 20 | $272 |
| Glycopyrrolate | 11 | $149 |
| Hydroxyzine Hcl | 12 | $148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $2,330 | $177,08328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 mohs-micrographic surgery providers in Washington.
Other mohs-micrographic surgery in Richland
- Ein Gun SongMill Creek$4.5M
- Marcus TanRenton$8K
- Mikel MuseVancouver$6K
- Jennifer ReichelSeattle$5K
- Kirk EcklundYakima$5K
- John NiaSpokane$5K
- Mustufa JafryMill Creek$4K
- Maureen MooneyUniversity Place$4K
- Nobuyoshi KageyamaRenton$4K
- Chadd SukutSpokane Valley$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.